6533b829fe1ef96bd1289b13

RESEARCH PRODUCT

Update on capecitabine alone and in combination regimens in colorectal cancer patients

Salvatore PiscontiEvaristo MaielloF. De VitaDaniela PetriellaA. MillakuGiuseppe ColucciStefania TommasiSaverio CinieriGianmauro NumicoVito LorussoAntonio RussoN. SilvestrisAmalia AzzaritiDaniele Santini

subject

OncologyOrganoplatinum CompoundsOxaloacetatesSettore MED/06 - Oncologia MedicaColorectal cancerLeucovorinCetuximabAdministration OralDeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsProdrugsAdjuvantCetuximabAntibodies MonoclonalGeneral MedicineNeoadjuvant TherapyOxaliplatinBevacizumabColorectal carcinomacolon cancerOncologyTolerabilityChemotherapy AdjuvantMetastaticFluorouracilNeoadjuvantColorectal Neoplasmsmedicine.drugDiarrheaAntimetabolites Antineoplasticmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleAdjuvant; Bevacizumab; Capecitabine; Cetuximab; Colorectal carcinoma; Irinotecan; Metastatic; Neoadjuvant; Oxaliplatin; Radiotherapy; Oncology; Radiology Nuclear Medicine and ImagingCapecitabineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingCapecitabineRadiotherapybusiness.industrymedicine.diseaseOxaliplatinClinical trialIrinotecanCamptothecinRadiotherapy Adjuvantbusiness

description

Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.

yearjournalcountryeditionlanguage
2010-01-01Cancer Treatment Reviews
https://doi.org/10.1016/s0305-7372(10)70020-7